Vitamin D Supplementation During the COVID-19 Pandemic.

To the Editor:

The coronavirus disease 2019 (COVID-19) pandemic has severe short-term and long-term consequences on individuals, health systems, and economies. Considering the studies on the role of vitamin D in the prevention of acute respiratory infections, supplementation of vitamin D may be reasonable also for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and reducing morbidity and mortality in COVID-19 high-risk patients.

Vitamin D deficiency is more common in older age groups, smokers, those who are obese, and in patients with chronic diseases such as diabetes, hypertension, various gastroenterological diseases, and also in African Americans. The high-risk groups that have more complications and higher mortality in COVID-19 coincide with groups that have a high incidence of vitamin D deficiency. We believe that vitamin D deficiency might be one of the important risk factors for COVID-19 complications and higher mortality.

Studies of vitamin D replacement have shown that vitamin D ameliorates innate immunity (the immediate response of macrophages to invading viruses and bacteria in the mucous membranes), thereby reducing the incidence and severity of acute respiratory infections. This effect requires a sufficient serum level of 25(OH)D3 being crucial for macrophages to activate it into hormone D (calcitriol), which activates genes for the synthesis of antimicrobial factors destroying viruses (such as SARS-CoV-2), fungi, and bacteria. Also, vitamin D modulates the cellular immune response and, as expected, attenuates the cytokine storm, the event so fatal in SARS-CoV-2–induced pneumonia. Therefore, we suggest it would be reasonable to supplement vitamin D in subpopulations at risk of vitamin D deficiency and unfavorable COVID-19 outcomes, as well as in individuals already infected with SARS-CoV-2 to achieve optimal 25(OH)D3 concentrations as quickly as possible.

It is challenging to conduct evidence-based medicine in cases such as the COVID-19 pandemic. To the best of our knowledge, there are no data on the effects of vitamin D in SARS-CoV-2 infection; then again, there are reliable data on the beneficial effects of cholecalciferol in attenuating viral respiratory infections in people with low levels of vitamin D. The European Centre for Disease Prevention and Control makes this argument and encourages health care professionals to take actions that are logical in their own right, based on previously known findings in related fields: “Public health authorities should recognize that extra-scientific factors (e.g. feasibility of implementing scientific advice, time pressure, socio-political factors, institutional factors, economic interests, pressure from neighboring countries etc.) are inherent to the decision-making process. These factors will also influence the implementation of any proposed response measures. Decisions should therefore always be evidence informed, but they will very rarely be purely evidence based.” In Slovenia, in view of COVID-19 pandemic, medical doctors were urgently advised by leading experts to supplement vitamin D in high-risk and fragile individuals and in COVID-19 patients. With this letter to the editor we address the broader medical community to urgently consider vitamin D supplementation in high-risk patients for adverse COVID-19 outcomes.